Extracellular vesicle-mediated crosstalk in bone: miR-150-5p as a mechanosensitive regulator of osteoclastogenesis

Read full text
Authors: Mimma Maggio, Carolina Martins, Rawan Almasri, S R Petrousek, Mathieu Y. Brunet, Luke Madden, Cansu Görgün, Tara Ní Néill, Fiona M. Roche, Conor Timothy Buckley, Lorraine O'Driscoll, David A. Hoey
Cited by: 1
References: 87

Abstract

Bone remodeling is essential for maintaining skeletal integrity by preserving the balance between bone formation and resorption, with excessive osteoclast activity contributing to osteoporosis. Osteocytes act as central regulators of osteoclastogenesis through mechanically sensitive paracrine signals, yet the influence of osteoblasts and their mesenchymal precursors remains less defined. Extracellular vesicles (EVs) have recently emerged as mediators of bone cell communication, although their role in osteoclast regulation is still underexplored. This study demonstrates that mesenchymal-derived bone cells inhibit osteoclastogenesis through an EV-dependent mechanism shaped by their differentiation stage and mechanical environment. Mechanically stimulated osteocyte-derived EVs showed the strongest anti-catabolic response. Notably, we identify miR-150-5p as a mechano-responsive miRNA enriched within osteocyte EVs, capable of inducing a dose-dependent reduction in osteoclastogenesis. Transcriptomic analyses reveal that EV treatment and miR-150-5p delivery induce substantial transcriptional changes in osteoclast precursors, including downregulation of shared target genes linked to bone remodeling. Overall, we highlight mechanically activated osteocytes as key regulators of osteoclastogenesis through an EV-mediated mechanism, in which miR-150-5p represents a promising candidate contributor within the broader EV cargo landscape, highlighting their potential for future cell-free therapeutic strategies.

Fields of Study & Subjects

Extracellular vesicles in disease Bone Metabolism and Diseases MicroRNA in disease regulation

Publication details

Journal / source
Molecular Therapy
Publisher
Elsevier BV
Volume
34
Issue
8
Pages
4942–4963
Publication date
1 May 2026
Language
EN